Theravance Biopharma, Inc. (TBPH) Earnings History
Annual and quarterly earnings data from 2011 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -72.9% | -87.6% |
| 2023 | 29.3% | -97.6% | -96.1% |
| 2022 | -23.5% | -179.1% | 1698.5% |
| 2021 | -250.1% | -466.1% | -360.6% |
| 2020 | 100.0% | -414.2% | -386.9% |
Download Data
Export TBPH earnings history in CSV or JSON format
Free sign-in required to download data
Theravance Biopharma, Inc. (TBPH) Earnings Overview
As of February 28, 2026, Theravance Biopharma, Inc. (TBPH) reported trailing twelve-month net income of $29M, reflecting -0.1% year-over-year growth. The company earned $0.57 per diluted share over the past four quarters, with a net profit margin of -0.9%.
Looking at the long-term picture, TBPH's historical earnings data spans multiple years. The company achieved its highest annual net income of $872M in fiscal 2022.
Theravance Biopharma, Inc. maintains positive profitability with a gross margin of 1.0%, operating margin of -0.7%, and net margin of -0.9%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including UTHR ($1.33B net income, 0.4% margin), ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), TBPH has room to improve margins relative to the peer group. Compare TBPH vs UTHR →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$56M | -2.2% | -$47M | $-1.15 | -87.6% | -72.9% |
| 2023 | -$55M | -106.3% | -$56M | $-1.00 | -96.1% | -97.6% |
| 2022 | $872M | +537.3% | -$92M | $-1.26 | 1698.5% | -179.1% |
| 2021 | -$199M | +28.3% | -$258M | $-2.87 | -360.6% | -466.1% |
| 2020 | -$278M | -17.6% | -$298M | $-4.46 | -386.9% | -414.2% |
| 2019 | -$236M | -9.7% | -$252M | $-4.25 | -322.1% | -343.1% |
| 2018 | -$216M | +24.5% | -$239M | $-3.99 | -357.0% | -395.5% |
| 2017 | -$285M | -49.7% | -$260M | $-5.45 | -1855.0% | -1690.6% |
| 2016 | -$191M | -4.6% | -$180M | $-4.26 | -391.9% | -371.0% |
| 2015 | -$182M | +23.1% | -$182M | $-5.34 | -432.6% | -431.8% |
See TBPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TBPH Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TBPH vs AGIO
See how TBPH stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TBPH growing earnings?
TBPH EPS of $0.57 reflects slowing growth at -0.1%, below the 5-year CAGR of N/A. TTM net income is $29M. Expansion rate has moderated.
What are TBPH's profit margins?
Theravance Biopharma, Inc. net margin is -0.9%, with operating margin at -0.7%. Below-average margins reflect competitive or cost pressures.
How consistent are TBPH's earnings?
TBPH earnings data spans 2011-2024. The current earnings trend is -0.1% YoY. Historical data enables comparison across business cycles.